Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articoli
Removing dietary copper starves leukemia cells of nucleotide building blocks, boosting methotrexate efficacy against hard-to-treat CNS disease.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
A landmark study of 500 cat tumors reveals shared cancer-driving mutations with humans, pointing toward new breast cancer treatments.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A phase II trial tests whether sunitinib retains activity in metastatic renal cell carcinoma after first-line immunotherapy resistance.
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
A Lancet Healthy Longevity editorial calls for systemic elevation of cancer survivorship care as a public health and longevity priority.
A newly discovered molecular pathway explains why many colorectal cancers resist immunotherapy — and points to a druggable target.
A landmark Cell study reveals cells transfer cytoplasmic DNA fragments to neighbors via nanotubes, stably reshaping recipient genomes.
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Adding an autophagy inhibitor to anlotinib plus PD-1 blockade dramatically reshapes the tumor microenvironment in NSCLC models.
